Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2014 L.P. Mpm Sells 14,569 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 14,569 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $7.06, for a total value of $102,857.14. Following the transaction, the insider owned 4,318,348 shares of the company’s stock, valued at $30,487,536.88. The trade was a 0.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Tuesday, August 25th, Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.54, for a total value of $199,975.88.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.34, for a total value of $158,712.82.

Entrada Therapeutics Stock Performance

NASDAQ TRDA traded down $0.62 during trading on Wednesday, hitting $7.00. 229,319 shares of the company’s stock traded hands, compared to its average volume of 334,500. The stock has a market capitalization of $272.58 million, a price-to-earnings ratio of -1.77 and a beta of -0.26. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45. The business has a 50 day moving average of $7.08 and a 200-day moving average of $9.36.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%. On average, analysts expect that Entrada Therapeutics, Inc. will post -4.03 EPS for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Baker BROS. Advisors LP lifted its stake in Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after purchasing an additional 206,911 shares in the last quarter. 5AM Venture Management LLC purchased a new position in shares of Entrada Therapeutics during the 2nd quarter valued at $29,854,949,000. GSA Capital Partners LLP purchased a new position in shares of Entrada Therapeutics during the 2nd quarter valued at $648,000. ADAR1 Capital Management LLC bought a new position in shares of Entrada Therapeutics in the second quarter worth $114,000. Finally, Nan Fung Group Holdings Ltd bought a new position in shares of Entrada Therapeutics in the second quarter worth $361,244,000. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. HC Wainwright lowered shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Weiss Ratings downgraded Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Guggenheim cut their price target on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Monday, June 8th. Finally, Roth Capital reiterated a “buy” rating and issued a $11.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.